key: cord-0840394-9jakiead
authors: Biyani, Chandra Shekhar; Palit, Victor; Daga, Sunil
title: The use of Captopril - angiotensin converting enzyme (ACE) inhibitor for cystinuria during COVID-19 pandemic
date: 2020-04-22
journal: Urology
DOI: 10.1016/j.urology.2020.04.057
sha: e8047c046364d2a4935e22f8e6bbc9ec929246c6
doc_id: 840394
cord_uid: 9jakiead

nan

2 Cystinuria is rare condition affecting around 1:2000 people in UK but is a chronic condition and presents with recurrent urolithiasis requiring multiple surgical interventions. Studies in adult has demonstrated higher prevalence of hypertension, and renal impairment. Apart from increase fluid intake, alkalinisation of urine and lower salt intake, thiols medications are important second line preventative strategies. There has been issues with supply of both D-Penicillamine and tiopronin and captopril is an easily available drug. Captopril, is the first ACE inhibitor (ACEi) in the market and is the only ACEi that has sulfhydryl ligand that forms bond with cystine. Cystine-Captopril disulphide is 200 times more soluble than cystine and thus prevent stone formation. Captopril has demonstrated to improve blood pressure and protect renal function. Hence it could be used in patients with cystinuria and other comorbidities. 1 It has been suggested that use of ACE inhibitors may exacerbate symptoms in COVID-19 patients and have led to controversies. 2 The angiotensin-converting enzyme 2 (ACE2), an enzyme that physiologically counters the renin-angitensin-aldesterone system activation but also functions as a receptor for COVID-19 virus and the COVID-19 S protein binds strongly to the ACE2 receptor. 3 Guan et al reported hypertension and diabetes as most common comorbidities in patents admitted with COVID-19 infection, however, treatment with ACE inhibitors was not evaluated separately. 4 A recent paper reported that acute cardiac injury and heart failure in addition to the acute lung injury may be responsible for severe illness with a high mortality. Interestingly, mortality rate was almost similar in patients with or without history of hypertension. 5 A sudden withdrawal of ACE inhibitors has been discouraged as this action may result in clinical instability. At present there is scarce data to support any change in practice.

Until further data are available, we should continue captopril to treat stone disease associated with cystinuria. This position is in line with other association and society guidance (Renal Association, UK and European Society of Cardiology).

Cystinuria -Diagnosis and management

Controversies of reninangiotensin system inhibition during the COVID-19 pandemic

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Clinical characteristics of coronavirus disease 2019 in China

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study